.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Fuji
Queensland Health
Accenture
Boehringer Ingelheim
Merck
Harvard Business School
US Army
Covington
QuintilesIMS

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,333,045

« Back to Dashboard

Which drugs does patent 6,333,045 protect, and when does it expire?


Patent 6,333,045 protects ZYMAR and is included in one NDA. There has been one Paragraph IV challenge on Zymar.

Protection for ZYMAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in fifteen countries.

Summary for Patent: 6,333,045

Title: Aqueous liquid pharmaceutical composition comprised of gatifloxacin
Abstract:There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazi nyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
Inventor(s): Yasueda; Shinichi (Kobe, JP), Inada; Katsuhiro (Kobe, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (Osaka, JP) Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:09/529,882
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
ZYMAR
gatifloxacin
SOLUTION/DROPS;OPHTHALMIC021493-001Mar 28, 2003RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,333,045

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10/235432Aug 21, 1998
PCT Information
PCT FiledAugust 20, 1999PCT Application Number:PCT/JP99/04483
PCT Publication Date:March 02, 2000PCT Publication Number: WO00/10570

International Patent Family for Patent: 6,333,045

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan5138128► Subscribe
Hong Kong1029934► Subscribe
Spain2264266► Subscribe
European Patent Office1025846► Subscribe
Denmark1025846► Subscribe
Germany69932313► Subscribe
China1133432► Subscribe
China1275081► Subscribe
Canada2307632► Subscribe
BrazilPI9906735► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
McKesson
Johnson and Johnson
Mallinckrodt
Harvard Business School
Healthtrust
Cantor Fitzgerald
Fish and Richardson
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot